Cover Image
市場調查報告書

Biotie Therapies Corp.:產品平台分析

Biotie Therapies Corp. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 214140
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
Back to Top
Biotie Therapies Corp.:產品平台分析 Biotie Therapies Corp. - Product Pipeline Review - 2015
出版日期: 2015年12月30日 內容資訊: 英文 34 Pages
簡介

Biotie Therapies Corp.是從事帕金森氏症和老年癡呆症等認知障礙的神經退化性疾病、精神疾病、發炎性疾病、纖維性疾病用治療藥物研究、開發之製藥企業。

本報告提供Biotie Therapies Corp.的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Biotie Therapies Corp.的基本資料

Biotie Therapies Corp.概要

  • 主要資訊
  • 企業資料

Biotie Therapies Corp.:R&D概要

  • 主要的治療範圍

Biotie Therapies Corp.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Biotie Therapies Corp.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Biotie Therapies Corp.:藥物簡介

  • nepicastat hydrochloride
  • tozadenant
  • BTT-1023
  • SYN-114
  • SYN-120
  • 阻礙思覺失調症的PDE-10的小分子

Biotie Therapies Corp.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Biotie Therapies Corp.:最近的開發平台趨勢

Biotie Therapies Corp.:暫停中的計劃

Biotie Therapies Corp.:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • buprenorphine hydrochloride
    • AWD-12281
    • BTT-1507
    • nitisinone
    • rufinamide

Biotie Therapies Corp.:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07937CDB

Summary

Global Markets Direct's, 'Biotie Therapies Corp. - Product Pipeline Review - 2015', provides an overview of the Biotie Therapies Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biotie Therapies Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Biotie Therapies Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biotie Therapies Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Biotie Therapies Corp.'s pipeline products

Reasons to buy

  • Evaluate Biotie Therapies Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biotie Therapies Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biotie Therapies Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biotie Therapies Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biotie Therapies Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biotie Therapies Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Biotie Therapies Corp. Snapshot
    • Biotie Therapies Corp. Overview
    • Key Information
    • Key Facts
  • Biotie Therapies Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Biotie Therapies Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Biotie Therapies Corp. - Pipeline Products Glance
    • Biotie Therapies Corp. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Biotie Therapies Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Biotie Therapies Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Biotie Therapies Corp. - Drug Profiles
    • tozadenant
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BTT-1023
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SYN-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Biotie Therapies Corp. - Pipeline Analysis
    • Biotie Therapies Corp. - Pipeline Products by Target
    • Biotie Therapies Corp. - Pipeline Products by Route of Administration
    • Biotie Therapies Corp. - Pipeline Products by Molecule Type
    • Biotie Therapies Corp. - Pipeline Products by Mechanism of Action
  • Biotie Therapies Corp. - Recent Pipeline Updates
  • Biotie Therapies Corp. - Dormant Projects
  • Biotie Therapies Corp. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • buprenorphine hydrochloride
      • AWD-12281
      • nitisinone
      • rufinamide
      • vepalimomab
  • Biotie Therapies Corp. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Biotie Therapies Corp., Key Information
  • Biotie Therapies Corp., Key Facts
  • Biotie Therapies Corp. - Pipeline by Indication, 2015
  • Biotie Therapies Corp. - Pipeline by Stage of Development, 2015
  • Biotie Therapies Corp. - Monotherapy Products in Pipeline, 2015
  • Biotie Therapies Corp. - Out-Licensed Products in Pipeline, 2015
  • Biotie Therapies Corp. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Biotie Therapies Corp. - Phase III, 2015
  • Biotie Therapies Corp. - Phase II, 2015
  • Biotie Therapies Corp. - Preclinical, 2015
  • Biotie Therapies Corp. - Pipeline by Target, 2015
  • Biotie Therapies Corp. - Pipeline by Route of Administration, 2015
  • Biotie Therapies Corp. - Pipeline by Molecule Type, 2015
  • Biotie Therapies Corp. - Pipeline Products by Mechanism of Action, 2015
  • Biotie Therapies Corp. - Recent Pipeline Updates, 2015
  • Biotie Therapies Corp. - Dormant Developmental Projects,2015
  • Biotie Therapies Corp. - Discontinued Pipeline Products, 2015
  • Biotie Therapies Corp., Other Locations
  • Biotie Therapies Corp., Subsidiaries

List of Figures

  • Biotie Therapies Corp. - Pipeline by Top 10 Indication, 2015
  • Biotie Therapies Corp. - Pipeline by Stage of Development, 2015
  • Biotie Therapies Corp. - Monotherapy Products in Pipeline, 2015
  • Biotie Therapies Corp. - Pipeline by Top 10 Target, 2015
  • Biotie Therapies Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Biotie Therapies Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Biotie Therapies Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top